Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer63

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer27

Views

Views
December 20250
January 20262
February 20260
March 20262
April 20268
May 20264
June 202611
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States15
Netherlands3
United Kingdom2
Italy2
Finland2
France1
Slovakia1
Uruguay1
 

Top cities views

Views
Groningen3
Helsinki2
Bardolino1
Boston1
Dacula1
Firminy1
Los Angeles1
Malacky1
Manchester1
Montevideo1